Latest Biotech News

Researchers reported a CRISPR/Cas9‑based strategy that precisely excises pathogenic GGC repeat expansions in NOTCH2NLC, a genetic cause of neuronal intranuclear inclusion disease (NIID). The work...

Oxford Nanopore secured CE‑marking under the EU IVDR and UKCA marking for its GridIon Dx sequencer, positioning the platform for clinical deployment in Europe and the UK; the company also named...

Nvidia and Eli Lilly announced a five-year, up-to-$1 billion co-investment to build an AI-focused drug discovery lab in San Francisco. The collaboration will place Nvidia engineers alongside Lilly...

Basecamp Research published a preprint and reported that its evolutionary AI family, EDEN, can design tools for programmable gene insertion across thousands of human genomic sites. Using ~9.7...

AbbVie agreed to license ex‑China rights to RemeGen’s PD‑1×VEGF bispecific (RC148), paying $650 million up front with potential milestones totaling several billion dollars. The deal, disclosed at...

Grail told investors at JP Morgan that it plans to submit its Galleri multi‑cancer early detection test to the FDA for premarket approval in Q1 2026 and projected full‑year 2025 revenue growth of...

10x Genomics announced three clinically focused collaborations and plans to open a CLIA‑certified lab in early 2027 to move single‑cell and spatial assays into regulated clinical workflows....

Tahoe Therapeutics, the Arc Institute and the Chan‑Zuckerberg Biohub committed multimillion‑dollar resources to build a perturbation‑heavy single‑cell dataset intended to power virtual cell...

A UC San Diego team published PanMAN (Pangenome Mutation‑Annotated Network), a new data structure and compression method that achieves up to ~1,391× file‑size reduction versus existing...

Trenchant BioSystems released internal and third‑party data for its AutoCell cell‑and‑gene therapy (CGT) manufacturing prototype, saying the platform can cut vein‑to‑vein timelines from ~6 weeks...

Tessera Therapeutics received FDA clearance of an IND and Australian HREC approval to initiate a Phase I/II study of TSRA‑196, its in‑vivo gene‑editing candidate for α‑1 antitrypsin deficiency...

Mirador Therapeutics closed a $250 million Series B to advance its precision immunology pipeline and signaled plans to consider an IPO later this year. The financing, led by major life‑science...

AbbVie struck an exclusive licensing deal with RemeGen to acquire rights to a PD‑1/VEGF bispecific antibody program, paying $650 million up front and agreeing to development and commercial...

Nvidia and Eli Lilly announced a joint, five‑year investment of up to $1 billion to build an AI drug‑discovery laboratory in San Francisco, committing infrastructure, compute and shared talent to...

Basecamp Research reported EDEN, an evolutionary AI family, can design enzymes that enable programmable insertion of large DNA sequences at specified genomic sites, demonstrating insertion at over...

Tahoe Therapeutics, the Arc Institute and Biohub announced a joint commitment to generate a publicly available, perturbation‑heavy single‑cell dataset aimed at training and validating virtual cell...

Oxford Nanopore announced CE‑IVDR and UKCA marking for its GridIon Dx sequencer, making it the company's first regulated IVD device in Europe and the UK and enabling clinical deployment in...

Trenchant Biosystems released internal and third‑party validation data for its AutoCell automated cell‑and‑gene‑therapy (CGT) manufacturing prototype, asserting it can reduce vein‑to‑vein...

10x Genomics announced three clinically oriented collaborations—Dana‑Farber, the Cancer Research Institute and Brigham and Women’s Hospital—aimed at generating large single‑cell and spatial...

Pacific Biosciences said it will collaborate with the n‑Lorem Foundation and EspeRare to study individualized antisense oligonucleotide (ASO) therapies, deploying PacBio HiFi long‑read...